Answers are grounded in this paper and cite their sources.
Pemphigus is a rare autoimmune bullous disease, and the best evidence-based approach to the management of this dermatosis is still a contentious issue. Therapeutic approaches must recognize the chronic, relapsing and remitting nature of the disease and that morbidity is mainly a result of treatment. Corticosteroids are the cornerstone of treatment; however, adjuvant therapies, such as azathioprine, mycophenolate mofetil, cyclophosphamide, and newer therapies, such as plasmapheresis, intravenous immunoglobulin and rituximab, are being increasingly utilized. At present, treatment regimes are ostensibly based on the clinical experience of the physician, rather than on empirical evidence, as research in the field of pemphigus is fraught with a number of intrinsic difficulties. This review aims to provide an evaluation of the different treatment options that are available and the evidence in the literature that advocates or opposes their use.
No takes yet. Share an insight, caveat, or question.
Sebaratnam et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: